To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer

Conditions: HR-positive, HER2-low Breast Cancer Interventions: Drug: Disitamab Vedotin for Injection; Drug: Toripalimab; Drug: Epirubicin; Drug: Cyclophosphamide Sponsors: RemeGen Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials